ERBB2 and breast carcinoma: Subsequently, the PHEDRA study conducted a randomized phase 3 trial of neoadjuvant pyrotinib, trastuzumab, and docetaxel in HER2-positive breast cancer, and the results confirmed that the tpCR rate in the pyrotinib group was 41.0% (95% CI 34.0–48.4), while 22.0% (95% CI 16.6–28.7) in the placebo group (difference 19.0% [95% CI 9.5–28.4]; Unilateral P < 0.0001) [19].